移植
免疫抑制
小岛
诱导多能干细胞
医学
胰岛细胞移植
免疫学
1型糖尿病
胚胎干细胞
生物信息学
生物
糖尿病
内科学
内分泌学
遗传学
基因
作者
Zofia Czarnecka,Nidheesh Dadheech,Haide Razavy,Rena Pawlick,A. M. James Shapiro
出处
期刊:Cells
[MDPI AG]
日期:2023-10-10
卷期号:12 (20): 2423-2423
标识
DOI:10.3390/cells12202423
摘要
Type 1 Diabetes (T1D) is an autoimmune destruction of pancreatic beta cells. The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. In 2022, the 20-year follow-up findings of islet cell transplantation demonstrated the long-term safety of islet cell transplantation despite chronic immunosuppression. The Edmonton Protocol, however, remains limited by two obstacles: scarce organ donor availability and risks associated with chronic immunosuppression. To overcome these challenges, the search has begun for an alternative cell source. In 2006, pluripotency genomic factors, coined “Yamanaka Factors,” were discovered, which reprogram mature somatic cells back to their embryonic, pluripotent form (iPSC). iPSCs can then be differentiated into specialized cell types, including islet cells. This discovery has opened a gateway to a personalized medicine approach to treating diabetes, circumventing the issues of donor supply and immunosuppression. In this review, we present a brief history of allogenic islet cell transplantation from the early days of pancreatic remnant transplantation to present work on encapsulating stem cell-derived cells. We review data on long-term outcomes and the ongoing challenges of allogenic islet cell and stem cell-derived islet cell transplant.
科研通智能强力驱动
Strongly Powered by AbleSci AI